High concentration of symmetric dimethylarginine is associated with low platelet reactivity and increased bleeding risk in patients with acute coronary syndrome

Eyileten, Ceren; Nowak, A; Jarosz-Popek, Joanna; Wolska, Marta; Dizdarevic, Al-Medina; Lang, Irene; Postuła, Marek; Ufnal, Marcin; Siller‐Matula, Jolanta M.

doi:10.1016/j.thromres.2022.03.025

Cited by 1 publication

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is concerning because it is an independent predictor of ischemic events such as stent thrombosis and myocardial infarction one year after the initial PCI, despite the low risk of bleeding [ 13 , 14 ]. In patients with coronary heart disease who underwent PCI, the combination of high baseline and post-treatment PARs was associated with a higher risk of recurrent ischemic events [ 15 , 16 ]. Björklund et al .…”

Section: Discussionmentioning

confidence: 99%

Effects of Body Mass Index and Body Weight on Plasma Concentration of Ticagrelor and Platelet Aggregation Rate in Patients with Unstable Angina in a Chinese Han Population

Guo,

Li,

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: The aim of this study was to investigate the impact of body mass index (BMI) and body weight on the concentrations of ticagrelor and the ticagrelor metabolite, AR-C124910XX, as well as the platelet aggregation rate (PAR) in a Chinese Han population with unstable angina (UA). Specifically, it focused on these parameters following the administration of dual antiplatelet therapy (DAPT) comprising aspirin and ticagrelor. Methods: A total of 105 patients with UA were included in the study. Measurement of the platelet aggregation rate induced by adenosine diphosphate (PAR-ADP) was performed before, as well as 3 and 30 days after DAPT treatment. The plasma concentrations of ticagrelor and AR-C124910XX were detected at 3 and 30 days after DAPT treatment. We conducted correlation analyses to assess the effects of BMI and body weight on the concentrations of ticagrelor and AR-C124910XX, on PAR-ADP, and on the inhibition of platelet aggregation induced by adenosine diphosphate (IPA-ADP) at both 3 and 30 days after DAPT treatment. Results: The BMI and body weight were positively correlated with baseline PAR-ADP ( r = 0.205, p = 0.007; r = 0.122, p = 0.022). The PAR-ADP at 3 and 30 days after DAPT treatment were significantly lower than at baseline (61.56% 10.62%, 8.02% 7.52%, 12.90% 7.42%, p 0.001). There was a negative correlation between body weight and the concentrations of ticagrelor and AR-C124910XX at 3 days following DAPT treatment ( r = –0.276, p 0.001; r = –0.337, p 0.001). Additionally, BMI showed a similar negative correlation with the concentrations of ticagrelor and AR-C124910XX ( r = –0.173, p = 0.009; r = –0.207, p = 0.002). At 30 days after treatment, both body weight and BMI were negatively correlated with ticagrelor ( r = –0.256, p 0.001; r = –0.162, p = 0.015) and its metabolite ( r = –0.352, p 0.001; r = –0.202, p = 0.002). Body weight was positively correlated with PAR-ADP ( r = 0.171, p = 0.010) and negatively correlated with IPA-ADP ( r = –0.163, p = 0.015) at 30 days after treatment. Similarly, BMI was positively correlated with PAR-ADP ( r = 0.217, p = 0.001) and negatively correlated with IPA-ADP ( ...

show abstract